AusperBio Secures $120M, Propels AHB-137 to Phase 3 for Hepatitis B Functional Cure
August 30, 2026, 9:37 am
AusperBio secured $120 million Series C, raising total capital to $360 million. This substantial funding accelerates its lead candidate, AHB-137, into a pivotal Phase 3 program for chronic hepatitis B. The company aggressively pursues a functional cure, a breakthrough for 250 million sufferers worldwide. Investment also boosts AHB-171, an siRNA therapy, and next-generation combination approaches. This aims to revolutionize HBV treatment, moving beyond lifelong management towards effective viral elimination and a definitive end to medication.
AusperBio commands attention. The biotechnology firm recently closed a significant $120 million Series C funding round. This latest infusion brings its total capital raised since 2024 to $360 million. The company targets one of the most pressing global health challenges: chronic hepatitis B (CHB). Its ambition is clear. AusperBio seeks a functional cure for millions afflicted by this liver disease.
Chronic hepatitis B represents a silent pandemic. Over 250 million people worldwide live with the infection. It silently progresses. Liver cirrhosis and cancer often result. Approximately 1.1 million deaths occur annually from HBV-related complications. Current treatments offer management. They suppress the virus. They rarely eradicate it. Patients face lifelong drug dependency. This imposes a heavy burden. The medical community desperately seeks a definitive solution.
AusperBio steps forward with an innovative approach. The company develops targeted oligonucleotide therapeutics. These advanced RNA drugs are designed to directly confront the hepatitis B virus. Their lead candidate, AHB-137, exemplifies this strategy.
AHB-137 is an antisense oligonucleotide (ASO). It targets crucial viral components. The drug suppresses hepatitis B surface antigen production. It inhibits viral DNA replication. Crucially, it promotes immune system reactivation. These combined actions aim to achieve a functional cure. This means the virus is controlled to the point where treatment can safely stop.
The progress of AHB-137 is rapid. The candidate is now advancing into a Phase 3 registrational program. This critical stage follows successful global Phase 1 and multiple Phase 2 studies. A Phase 3 trial in China is underway. This marks a pivotal step toward potential regulatory approval.
AusperBio's pipeline extends beyond AHB-137. The company actively develops AHB-171. This is a different type of RNA drug, a small interfering RNA (siRNA). AHB-171 operates on a complementary mechanism. It selectively suppresses viral gene expression. This broadens the therapeutic attack on HBV.
AHB-171 leverages AusperBio’s proprietary Au-HALO™ targeted delivery platform. Effective delivery of RNA drugs to the liver, where HBV resides, has been a significant hurdle. The Au-HALO™ platform aims to overcome this. It ensures the therapeutic payload reaches its target efficiently. AHB-171 represents the first clinical candidate utilizing this innovative platform.
The fresh capital injection fuels multiple strategic initiatives. A primary focus is accelerating AHB-137 through its Phase 3 trials. This is the final, most extensive study required before applying for regulatory approval. AusperBio simultaneously builds commercialization readiness. This ensures rapid market deployment if trial data proves successful.
A significant portion of the funding also supports AHB-171. Accelerating its development strengthens AusperBio’s position. It provides a second promising candidate in the fight against chronic hepatitis B. Further, the company plans to expand its broader oligonucleotide pipeline. This involves exploring targeted therapies for other diseases with high unmet medical needs.
Beyond single-agent therapies, AusperBio actively explores combination approaches. Using multiple drugs together could enhance efficacy. This strategy aims for deeper, more durable antiviral responses. It seeks to push patients closer to a lasting functional cure.
The Series C round saw strong investor confidence. A leading strategic investor led the financing. New investor RA Capital Management joined the round. Existing backers also participated. These included HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. Their continued support validates AusperBio's scientific platform and strategic vision.
AusperBio stands at an inflection point. Its efforts could redefine chronic hepatitis B treatment. A successful AHB-137 in Phase 3 would be monumental. It could be among the first new HBV drugs in years offering a real chance to stop therapy. This would fundamentally shift the standard of care. It would move from lifelong viral management to a potential cure.
The broader landscape of RNA medicine supports AusperBio’s ambition. ASOs and siRNAs have demonstrated efficacy in other diseases. AusperBio applies this proven science to HBV. Its Au-HALO™ platform is central to this application. It promises to overcome the critical delivery challenges specific to the liver.
The global health implications are profound. A functional cure for hepatitis B would save countless lives. It would reduce the incidence of liver cancer and cirrhosis. It would alleviate the immense healthcare burden. AusperBio’s $120 million funding pushes this critical goal significantly closer. It offers new hope to over a quarter billion people worldwide.
AusperBio commands attention. The biotechnology firm recently closed a significant $120 million Series C funding round. This latest infusion brings its total capital raised since 2024 to $360 million. The company targets one of the most pressing global health challenges: chronic hepatitis B (CHB). Its ambition is clear. AusperBio seeks a functional cure for millions afflicted by this liver disease.
Chronic hepatitis B represents a silent pandemic. Over 250 million people worldwide live with the infection. It silently progresses. Liver cirrhosis and cancer often result. Approximately 1.1 million deaths occur annually from HBV-related complications. Current treatments offer management. They suppress the virus. They rarely eradicate it. Patients face lifelong drug dependency. This imposes a heavy burden. The medical community desperately seeks a definitive solution.
AusperBio steps forward with an innovative approach. The company develops targeted oligonucleotide therapeutics. These advanced RNA drugs are designed to directly confront the hepatitis B virus. Their lead candidate, AHB-137, exemplifies this strategy.
AHB-137 is an antisense oligonucleotide (ASO). It targets crucial viral components. The drug suppresses hepatitis B surface antigen production. It inhibits viral DNA replication. Crucially, it promotes immune system reactivation. These combined actions aim to achieve a functional cure. This means the virus is controlled to the point where treatment can safely stop.
The progress of AHB-137 is rapid. The candidate is now advancing into a Phase 3 registrational program. This critical stage follows successful global Phase 1 and multiple Phase 2 studies. A Phase 3 trial in China is underway. This marks a pivotal step toward potential regulatory approval.
AusperBio's pipeline extends beyond AHB-137. The company actively develops AHB-171. This is a different type of RNA drug, a small interfering RNA (siRNA). AHB-171 operates on a complementary mechanism. It selectively suppresses viral gene expression. This broadens the therapeutic attack on HBV.
AHB-171 leverages AusperBio’s proprietary Au-HALO™ targeted delivery platform. Effective delivery of RNA drugs to the liver, where HBV resides, has been a significant hurdle. The Au-HALO™ platform aims to overcome this. It ensures the therapeutic payload reaches its target efficiently. AHB-171 represents the first clinical candidate utilizing this innovative platform.
The fresh capital injection fuels multiple strategic initiatives. A primary focus is accelerating AHB-137 through its Phase 3 trials. This is the final, most extensive study required before applying for regulatory approval. AusperBio simultaneously builds commercialization readiness. This ensures rapid market deployment if trial data proves successful.
A significant portion of the funding also supports AHB-171. Accelerating its development strengthens AusperBio’s position. It provides a second promising candidate in the fight against chronic hepatitis B. Further, the company plans to expand its broader oligonucleotide pipeline. This involves exploring targeted therapies for other diseases with high unmet medical needs.
Beyond single-agent therapies, AusperBio actively explores combination approaches. Using multiple drugs together could enhance efficacy. This strategy aims for deeper, more durable antiviral responses. It seeks to push patients closer to a lasting functional cure.
The Series C round saw strong investor confidence. A leading strategic investor led the financing. New investor RA Capital Management joined the round. Existing backers also participated. These included HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. Their continued support validates AusperBio's scientific platform and strategic vision.
AusperBio stands at an inflection point. Its efforts could redefine chronic hepatitis B treatment. A successful AHB-137 in Phase 3 would be monumental. It could be among the first new HBV drugs in years offering a real chance to stop therapy. This would fundamentally shift the standard of care. It would move from lifelong viral management to a potential cure.
The broader landscape of RNA medicine supports AusperBio’s ambition. ASOs and siRNAs have demonstrated efficacy in other diseases. AusperBio applies this proven science to HBV. Its Au-HALO™ platform is central to this application. It promises to overcome the critical delivery challenges specific to the liver.
The global health implications are profound. A functional cure for hepatitis B would save countless lives. It would reduce the incidence of liver cancer and cirrhosis. It would alleviate the immense healthcare burden. AusperBio’s $120 million funding pushes this critical goal significantly closer. It offers new hope to over a quarter billion people worldwide.